We are live on
!
Find out more
CCM
Cupps Capital Management Portfolio holdings
AUM
$231M
1-Year Est. Return
49.73%
This Fund
S&P 500
This Quarter
Est. Return
+19.18%
1 Year Est. Return
+49.73%
3 Year Est. Return
+212.7%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$231M
AUM Growth
-$156M
(-40%)
Cap. Flow
-$194M
Cap. Flow
% of AUM
-83.99%
Top 10 Holdings %
Top 10 Hldgs %
24.21%
Holding
206
New
45
Increased
20
Reduced
112
Closed
29
Top Buys
| 1 |
MDSO
Medidata Solutions, Inc.
MDSO
|
+$2.5M |
| 2 |
Glaukos
GKOS
|
+$2.17M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$1.61M |
| 4 |
CAVM
Cavium, Inc.
CAVM
|
+$1.52M |
| 5 |
BLUE
bluebird bio
BLUE
|
+$1.51M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$9.12M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$8.36M |
| 3 |
Amazon
AMZN
|
+$7.51M |
| 4 |
Burlington
BURL
|
+$6.63M |
| 5 |
Texas Roadhouse
TXRH
|
+$5.36M |
Sector Composition
| 1 | Technology | 39.39% |
| 2 | Healthcare | 24.2% |
| 3 | Consumer Discretionary | 10.03% |
| 4 | Industrials | 9.46% |
| 5 | Real Estate | 3.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVRO
1
DELISTED
NEVRO CORP.
NVRO
| $9.06M | 3.92% |
86,799
-92,571
| -52% | -$8.36M |
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $7.78M | 3.37% |
60,492
-76,161
| -56% | -$9.12M |
|
|
ZEN
3
DELISTED
ZENDESK INC
ZEN
| $6.12M | 2.65% |
199,196
-9,557
| -5% | -$284K |
|
4
Paycom
PAYC
$6.9B
| $6M | 2.6% |
119,720
-63,505
| -35% | -$3.1M |
|
5
Tyler Technologies
TYL
$13.1B
| $5.85M | 2.53% |
34,160
-25,359
| -43% | -$4.23M |
|
|
PFPT
6
DELISTED
Proofpoint, Inc.
PFPT
| $5.12M | 2.22% |
68,466
-18,934
| -22% | -$1.4M |
|
|
ULTI
7
DELISTED
Ultimate Software Group Inc
ULTI
| $4.12M | 1.78% |
20,162
-15,107
| -43% | -$3.19M |
|
|
TWOU
8
DELISTED
2U Inc
TWOU
| $4.02M | 1.74% |
3,504
+435
| +14% | +$454K |
|
|
9
Burlington
BURL
$21.7B
| $3.93M | 1.7% |
48,502
-85,690
| -64% | -$6.63M |
|
10
Vail Resorts
MTN
$5.27B
| $3.92M | 1.7% |
24,982
-16,472
| -40% | -$2.51M |
|
|
NEWR
11
DELISTED
New Relic, Inc.
NEWR
| $3.8M | 1.64% |
99,180
-47,354
| -32% | -$1.66M |
|
|
ELLI
12
DELISTED
Ellie Mae Inc
ELLI
| $3.69M | 1.6% |
35,092
+592
| +2% | +$57.4K |
|
|
BERY
13
DELISTED
Berry Global Group, Inc.
BERY
| $3.58M | 1.55% |
88,785
-38,949
| -30% | -$1.53M |
|
14
HubSpot
HUBS
$11.5B
| $3.51M | 1.52% |
60,930
-15,410
| -20% | -$836K |
|
|
CAVM
15
DELISTED
Cavium, Inc.
CAVM
| $3.31M | 1.43% |
56,822
+30,356
| +115% | +$1.52M |
|
16
MACOM Technology Solutions
MTSI
$20.4B
| $3.2M | 1.39% |
75,645
-14,320
| -16% | -$561K |
|
17
Edwards Lifesciences
EW
$49.4B
| $2.8M | 1.21% |
69,681
-121,311
| -64% | -$4.57M |
|
18
DexCom
DXCM
$29.6B
| $2.69M | 1.16% |
122,736
-156,288
| -56% | -$3.48M |
|
|
MDSO
19
DELISTED
Medidata Solutions, Inc.
MDSO
| $2.63M | 1.14% |
+47,254
| New | +$2.5M |
|
20
Applied Materials
AMAT
$421B
| $2.62M | 1.13% |
86,871
-99,980
| -54% | -$2.79M |
|
|
21
Glaukos
GKOS
$9.21B
| $2.48M | 1.07% |
+65,680
| New | +$2.17M |
|
22
Electronic Arts
EA
$52.4B
| $2.43M | 1.05% |
28,413
-14,229
| -33% | -$1.14M |
|
23
XPO
XPO
$25.2B
| $2.35M | 1.02% |
185,656
+79,120
| +74% | +$895K |
|
24
Nektar Therapeutics
NKTR
$2.31B
| $2.33M | 1.01% |
9,027
-2,143
| -19% | -$552K |
|
|
NXTM
25
DELISTED
NxStage Medical Inc.
NXTM
| $2.29M | 0.99% |
91,711
-5,024
| -5% | -$117K |
|
Similar funds
SA
WIM
EDRE
RIG
VBCP
TI
ZBI
MI
Cupps Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, Cupps Capital Management held 206 positions worth $231M, down 40% from $387M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Cupps Capital Management withdrew a net $194M in Q3 2016, closing 29 positions and reducing 112 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $3.68M position sold in full.
By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Cupps Capital Management opened a new position in Medidata Solutions, Inc. worth $2.63M.
- Cupps Capital Management's largest Q3 2016 buy was Medidata Solutions, Inc.: 47,254 shares worth $2.63M.
- Cupps Capital Management added most to Cavium, Inc. in Q3 2016, an estimated $1.52M increase.
- Cupps Capital Management's biggest Q3 2016 reduction was Abiomed Inc, cutting an estimated $9.12M.
- Cupps Capital Management fully exited Bristol-Myers Squibb in Q3 2016, selling an estimated $3.68M.
- Cupps Capital Management's ten largest holdings make up 24% of its $231M portfolio in Q3 2016.
- Cupps Capital Management opened 45 new positions and closed 29 in Q3 2016.
- Cupps Capital Management's portfolio value fell 40% quarter-over-quarter to $231M.
Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.